Kuhn 2003.

Study characteristics
Methods	A single‐centre, non‐randomised, prospective study (Germany) Baseline period: 4 days Observation period: 20 to 30 weeks
Participants	75 people with temporal lobe epilepsy exceeding 15 points on the HAMD‐21 scale for depression 45 females and 30 males Aged 19 to 68 years: mean 40.1 years
Interventions	Citalopram (N = 33), dose at endpoint: 24.2 mg Mirtazapine (N = 27), dose at endpoint: 32.2 mg Reboxetine (N = 15), dose at endpoint: 6.9 mg
Outcomes	1) Improvement in depressive symptoms 2) Seizure frequency and severity 3) Adverse effects
Notes	Large amount of withdrawals from week 4 to weeks 20 to 30. Last observation carried forward approach used